According to our latest study on "Bioproduction Market Forecast to 2030 - Global Analysis - by Product, Application, Equipment, and End User," the bioproduction market value is expected to reach US$ 63,393.93 million in 2030 from US$ 22,337.24 million in 2022. The report emphasizes the key factors driving the market and prominent players with their developments. The rising adoption of regenerative medicines and the increasing prevalence of chronic diseases are the key driving factors behind the market development. However, the high cost of cell therapy and biosimilar manufacturing is hampering the market growth.

Biosimilars are safe and efficient treatments for a wide range of disorders, including cancer, irritable bowel syndrome, psoriasis, Crohn's disease, and colitis, as well as arthritis and kidney problems. Biosimilars might result in cheaper costs as compared to biologics. Medications classified as biologics are those that are derived from living things, such as bacteria and yeast, microorganisms, and animal cells. This distinguishes biologics from traditional drugs, which are typically derived from chemicals. A wide range of illnesses with unmet medical needs, such as cancer, diabetes, cystic fibrosis, chronic renal disease, and autoimmune disorders, can be prevented, treated, or cured with biologics. Biosimilars are similar to the original biologic in terms of safety and efficacy. The FDA carefully and thoroughly reviews both before approving them. Manufacturers must demonstrate that patients using biosimilars do not have any new or worsening side effects in comparison to those using the original biologics in order for the FDA to approve the product.

The North America bioproduction market is sub-segmented into the US, Canada, and Mexico. In Mexico, the demand for cell therapy is quite noteworthy owing to growing medical tourism for stem cell therapy. The bioproduction market in North America accounted for the largest market share in 2022 due to the increasing incidence of diabetes and infertility, as well as rising product developments in biosimilars. Growing incidences of genetic and cellular disorders are leading to increasing demand for cell therapies. A 2020 PhRMA report on the cell and gene therapy pipeline revealed that there are 400 cell and gene therapies in development to target a variety of diseases and conditions in the US, from cancer to genetic disorders to neurological conditions. As of February 2020, nine cell or gene therapy products were approved in the US to treat cancer, eye diseases, and rare hereditary diseases. Also, an increasing number of start-ups are innovating cell therapies in the country.

In the US, biosimilars are used to treat patients with cancers, kidney diseases, diabetes, and other autoimmune diseases such as Crohn's disease and rheumatoid arthritis. According to Cardinal Health, a total of 33 biosimilars have been approved by the FDA in the US, and 21 are commercially available. Of the 21 biosimilars in the market, 17 are used for treatments associated with cancers, three are used to treat autoimmune conditions, and one is used to treat diabetes. Biosimilars are anticipated to be priced 15% to 30% lower than the biologics. In 2020 alone, biosimilars saved US$ 7.9 billion, with savings estimated to grow substantially in the next few years as more biosimilars enter the market. According to Cardinal Health, biosimilars are expected to reduce US drug expenditure by US$ 133 billion by 2025. In addition, growing support from the government is enhancing the growth of cell therapies, which is influencing the growth of the bioproduction market.

Lonza Group AG, bbi-biotech GmbH, Danaher Corp, Sartorius AG, FUJIFILM Irvine Scientific Inc, Thermo Fisher Scientific Inc, Merck KGaA, F. Hoffmann-La Roche Ltd, and Bio-Rad Laboratories Inc are the prominent bioproduction market players.

Companies operating in the bioproduction market adopt various organic and inorganic strategies. Growth strategies mainly include product launches and product approvals, mergers & acquisitions, collaborations, and partnerships are among the growth strategies witnessed in the bioproduction market.

A few of the significant developments by key market players are listed below.

- Various initiatives taken by leading players operating in the global bioproduction market are listed below:

- In March 2023, Lonza declared that its intended cGMP clinical and commercial drug product production line in Visp (CH) had been completed. Customers with a range of production demands for drug products, for both clinical and commercial supply, will be served by the new line. Modern liquid and lyophilized vial filling isolator line for multiple modalities that satisfies the GMP Annex 1 requirement for manufacturing sterile products is part of this 1,200 square meter cGMP facility. The line is already completely operating and has a cGMP license; in April 2023, the first client batches are scheduled to be filled.

- In October 2023, Lonza declared the continuation of a long-term partnership with a significant international biopharmaceutical partner. The extension of the agreement will add two new bioconjugation suites for the commercial supply of ADCs at Lonza's Ibex